174 related articles for article (PubMed ID: 15843784)
1. Palifermin (Kepivance) for myelotoxic-therapy-related mucositis.
Med Lett Drugs Ther; 2005 Apr; 47(1207):36. PubMed ID: 15843784
[TBL] [Abstract][Full Text] [Related]
2. Palifermin for oral mucositis after intensive therapy for hematologic cancers.
Spielberger R; Stiff P; Bensinger W; Gentile T; Weisdorf D; Kewalramani T; Shea T; Yanovich S; Hansen K; Noga S; McCarty J; LeMaistre CF; Sung EC; Blazar BR; Elhardt D; Chen MG; Emmanouilides C
N Engl J Med; 2004 Dec; 351(25):2590-8. PubMed ID: 15602019
[TBL] [Abstract][Full Text] [Related]
3. Palifermin (Kepivance) for the treatment of oral mucositis in patients with hematologic malignancies requiring hematopoietic stem cell support.
Radtke ML; Kolesar JM
J Oncol Pharm Pract; 2005 Sep; 11(3):121-5. PubMed ID: 16390600
[TBL] [Abstract][Full Text] [Related]
4. Palifermin: role in the prevention of chemotherapy- and radiation-induced mucositis.
McDonnell AM; Lenz KL
Ann Pharmacother; 2007 Jan; 41(1):86-94. PubMed ID: 17190850
[TBL] [Abstract][Full Text] [Related]
5. Palifermin: new drug. Prevention of oral mucositis: inappropriate evaluation.
Prescrire Int; 2007 Aug; 16(90):135-8. PubMed ID: 17724832
[TBL] [Abstract][Full Text] [Related]
6. Mucosal protection by cytokines.
Hofmeister CC; Stiff PJ
Curr Hematol Rep; 2005 Nov; 4(6):446-53. PubMed ID: 16232381
[TBL] [Abstract][Full Text] [Related]
7. The influence of palifermin (Kepivance) on oral mucositis and acute graft versus host disease in patients with hematological diseases undergoing hematopoietic stem cell transplant.
Nasilowska-Adamska B; Rzepecki P; Manko J; Czyz A; Markiewicz M; Federowicz I; Tomaszewska A; Piatkowska-Jakubas B; Wrzesien-Kus A; Bieniaszewska M; Duda D; Szydlo R; Halaburda K; Szczepinski A; Lange A; Hellman A; Robak T; Skotnicki A; Jedrzejczak WW; Walewski J; Holowiecki J; Komarnicki M; Dmoszynska A; Warzocha K; Marianska B
Bone Marrow Transplant; 2007 Nov; 40(10):983-8. PubMed ID: 17846600
[TBL] [Abstract][Full Text] [Related]
8. Economic impact of palifermin on the costs of hospitalization for autologous hematopoietic stem-cell transplant: analysis of phase 3 trial results.
Elting LS; Shih YC; Stiff PJ; Bensinger W; Cantor SB; Cooksley C; Spielberger R; Emmanoulides C
Biol Blood Marrow Transplant; 2007 Jul; 13(7):806-13. PubMed ID: 17580258
[TBL] [Abstract][Full Text] [Related]
9. Palifermin reduces patient-reported mouth and throat soreness and improves patient functioning in the hematopoietic stem-cell transplantation setting.
Stiff PJ; Emmanouilides C; Bensinger WI; Gentile T; Blazar B; Shea TC; Lu J; Isitt J; Cesano A; Spielberger R
J Clin Oncol; 2006 Nov; 24(33):5186-93. PubMed ID: 16391299
[TBL] [Abstract][Full Text] [Related]
10. Is oral mucositis an inevitable consequence of intensive therapy for hematologic cancers?
Sonis ST
Nat Clin Pract Oncol; 2005 Mar; 2(3):134-5. PubMed ID: 16264905
[No Abstract] [Full Text] [Related]
11. Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy.
Rosen LS; Abdi E; Davis ID; Gutheil J; Schnell FM; Zalcberg J; Cesano A; Gayko U; Chen MG; Clarke S
J Clin Oncol; 2006 Nov; 24(33):5194-200. PubMed ID: 17075109
[TBL] [Abstract][Full Text] [Related]
12. Reduction of radiochemotherapy-induced early oral mucositis by recombinant human keratinocyte growth factor (palifermin): experimental studies in mice.
Dörr W; Bässler S; Reichel S; Spekl K
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):881-7. PubMed ID: 15936573
[TBL] [Abstract][Full Text] [Related]
13. Palifermin for prevention of oral mucositis after haematopoietic stem cell transplantation- single centre experience.
Rzepecki P; Sarosiek T; Barzal J; Oborska S; Nurzynski P; Wasko A; Szczylik C
J BUON; 2007; 12(4):477-82. PubMed ID: 18067205
[TBL] [Abstract][Full Text] [Related]
14. New strategies for management of oral mucositis in cancer patients.
Peterson DE
J Support Oncol; 2006 Feb; 4(2 Suppl 1):9-13. PubMed ID: 16499139
[TBL] [Abstract][Full Text] [Related]
15. Palifermin and chemotherapy-induced oral mucositis.
Palmieri C; Vigushin D
N Engl J Med; 2005 Mar; 352(12):1264-5; author reply 1264-5. PubMed ID: 15791703
[No Abstract] [Full Text] [Related]
16. Palifermin for patients with haematological malignancies: shifting nursing practice from symptom relief to prevention of oral mucositis.
Fliedner M; Baguet B; Blankart J; Davies M; Henriques E; Leather A; Mazur E; Mihály K; Peeters L; Radványiné A; Sedlackova B
Eur J Oncol Nurs; 2007; 11 Suppl 1():S19-26. PubMed ID: 17540295
[TBL] [Abstract][Full Text] [Related]
17. Palifermin and chemotherapy-induced oral mucositis.
Köstler WJ; Hejna M; Zielinski CC
N Engl J Med; 2005 Mar; 352(12):1264-5; author reply 1264-5. PubMed ID: 15791702
[No Abstract] [Full Text] [Related]
18. Pharmacokinetic evaluation of palifermin for mucosal protection from chemotherapy and radiation.
Weigelt C; Haas R; Kobbe G
Expert Opin Drug Metab Toxicol; 2011 Apr; 7(4):505-15. PubMed ID: 21417820
[TBL] [Abstract][Full Text] [Related]
19. Palifermin and chemotherapy-induced oral mucositis.
Awada A; Genot MT; Klastersky J
N Engl J Med; 2005 Mar; 352(12):1264-5; author reply 1264-5. PubMed ID: 15788506
[No Abstract] [Full Text] [Related]
20. Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma.
Brizel DM; Murphy BA; Rosenthal DI; Pandya KJ; Glück S; Brizel HE; Meredith RF; Berger D; Chen MG; Mendenhall W
J Clin Oncol; 2008 May; 26(15):2489-96. PubMed ID: 18487568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
